GlassScriptPhysician profile
James K Treadway
NPI 1578733366
$3,032.39
in general payments reported to CMS, 2019-2025
31 companies · $872 in 2025
The $872 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $300 · 2021: $319 · 2022: $164 · 2023: $411 · 2024: $786 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,068.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $977.26 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $319.27 | 2019-2025 | Penmenvy, Bexsero, Rotarix |
| Corium, LLC | $305.06 | 2022-2025 | Azstarys |
| Tris Pharma INC | $271.90 | 2019-2025 | Onyda Xr |
| Ironshore Pharmaceuticals INC. | $182.28 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $170.70 | 2019-2024 | Vaxelis, Gardasil 9, M-M-R II |
| Pfizer INC. | $138.40 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $71.78 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $65.12 | 2025 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $62.93 | 2025 | Zoryve |
| Cranial Technologies, INC | $43.17 | 2024-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $37.03 | 2021 | |
| Avion Pharmaceuticals | $32.29 | 2022-2023 | Balcoltra |
| Sobi, INC | $31.27 | 2020-2022 | |
| Mylan Pharmaceuticals INC. | $28.58 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $25.23 | 2023 | |
| Seqirus USA INC | $24.82 | 2025 | Flucelvax |
| Genzyme Corporation | $24.44 | 2024 | |
| Sanofi Pasteur INC. | $23.94 | 2023 | |
| Verrica Pharmaceuticals INC. | $22.78 | 2025 | Ycanth |
| Rhodes Pharmaceuticals L.P. | $20.76 | 2019 | |
| Acadia Pharmaceuticals INC | $20.37 | 2023 | Daybue |
| Millicent US INC | $17.42 | 2025 | Femlyv |
| Neos Therapeutics, LP | $17.38 | 2021 | |
| Kaleo, INC. | $16.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.74 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.67 | 2025 | Alvesco |
| Cipher Pharmaceuticals US LLC | $14.09 | 2025 | Natroba, Spinosad |
| Genentech USA, INC. | $14.02 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.90 | 2019 | |
| Phadia US INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Treadway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.